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Inorganic arsenic, a metalloid, is ubiquitously
distributed in nature. In natural deposits, this
metalloid forms a complex with pyrite, for
which it has a strong affinity (Nordstrom
2002). However, under certain conditions
(pH, temperature, etc.), inorganic arsenic read-
ily dissociates from its soil-bound forms and
enters the aquifer (Smedley and Kinniburgh
2002). For this reason, the major source of
human exposure to arsenic is naturally conta-
minated drinking water from underground
wells. Probably more than 100 million people
are exposed to inorganic arsenic at levels above
10 µg/L, the drinking-water standard in many
countries [International Agency for Research
on Cancer (IARC) 2004]. Arsenic is also
released into the atmosphere from both natural
and anthropogenic sources. Globally, natural
emissions of arsenical compounds have been
estimated at about 8,000 tons each year,
whereas anthropogenic emissions are about
3 times higher [National Research Council
(NRC) 1999, 2001]. Food, particularly vegeta-
bles and rice, may be an additional source of
exposure to inorganic arsenic (NRC 1999,
2001). Occupational exposure to arsenic
occurs in specific industries such as mining,
smelting operations, wood preservation, and
electronics (IARC 2004). 
Arsenical exposure produces various
adverse effects such as dermal lesions, hyper-
tension, ischemic heart disease, liver disease,
peripheral vascular disorders, arteriosclerosis,
diabetes, neuropathy, and cancer (NRC 1999,
2001). The carcinogenic potential of inorganic
arsenic exposure through drinking water in
humans is a cause for considerable concern
[IARC 2004; NRC 1999, 2001; National
Toxicology Program (NTP) 2004]. Indeed,
inorganic arsenic is a potent, multisite human
carcinogen most frequently associated with
tumors of the skin, urinary bladder, and lung
(IARC 2004; NRC 1999, 2001; NTP 2004).
There are also human data associating inor-
ganic arsenic exposure with cancers of the liver,
prostate, and kidney. The mechanisms by
which inorganic arsenic is carcinogenic are not
completely defined (Kitchin 2001; Rossman
2003; Simeonova and Luster 2000; Waalkes
et al. 2007). A challenge to elucidating these
mechanisms has been the difficulty encoun-
tered in the development of experimental
whole animal models of arsenic carcinogenesis.
In essence, it has proven difﬁcult until recently
to induce cancer in animals using inorganic
arsenic as a single agent (Waalkes et al. 2007).
In place of whole animal models, cell lines
such as human prostate epithelial cells
(Achanzar et al. 2002), keratinocytes (Pi et al.
2003), and urothelial cells (Sens et al. 2004),
which may represent in vivo targets of arsenic,
provide a relevant and reasonable in vitro
approach to study the molecular events in
inorganic arsenic carcinogenesis. 
Arsenic toxicokinetics and metabolism.
The metabolism of arsenic compounds in
mammals has been reviewed (Aposhian and
Aposhian 2006; Styblo et al. 2002; Thomas
et al. 2001). Inorganic arsenic is well absorbed
from the gastrointestinal tract and distributed
throughout the body (NRC 2001). It freely
crosses the rodent and human placenta (NRC
1999). In many tissues inorganic arsenic is
biotransformed by methylation (NRC 2001).
Some cells methylate inorganic arsenic very
poorly or not at all, for example, keratinocytes
(Patterson et al. 2003) or prostate epithelial
cells (Benbrahim-Tallaa et al. 2005a).
Biomethylation of arsenic is no longer consid-
ered a detoxification process, as trivalent
methylated arsenical intermediates are highly
toxic (Mass et al. 2001; Styblo et al. 2000;
Wei et al. 2002) and possibly carcinogenic
(Bredfeldt et al. 2006). Reduction of arsenate
(As5+) to arsenite (As3+) is necessary before
methylation can occur. Arsenate is rapidly
reduced to arsenite by glutathione S-trans-
ferase omega and/or arsenate reductase.
Arsenite is then methylated to form methylar-
sonate (MMA5+) and dimethylarsinic acid
(DMA5+) by arsenic methyltransferase using
S-adenosylmethionine (SAM) as the methyl
donor. The intermediate metabolites methyl-
arsonous acid (MMA3+) and dimethylarsinous
acid (DMA3+) are generated during this
process (Aposhian and Aposhian 2006; Styblo
et al. 2000). The precise role of trivalent
methylated arsenical species in inorganic
arsenic carcinogenesis is not fully understood,
although MMA3+ can induce malignant trans-
formation of human urothelial cells in vitro
(Bredfeldt et al. 2006).
Both arsenite and arsenate are actively
transported into cells (Huang and Lee 1996;
Liu et al. 2002) by mechanisms that may
involve organic ion transporters (Bridges and
Zalups 2005). Recent evidence indicates that
multidrug resistance protein 1 (MRP1), an
ATP-binding cassette transport protein, is
involved in efﬂux of arsenite in an ATP- and
glutathione-dependent manner. It appears
arsenic is efﬂuxed as a triglutathione complex
(Leslie et al. 2004) produced by glutathione
S-transferase pi (Liu et al. 2001), which may
stress cellular redox systems from continuous
demands on glutathione. 
Prostate cancer. The prostate gland is char-
acterized by the age-dependent development of
abnormal proliferative diseases ranging from
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cies. Prostate cancer is the most frequently
diagnosed non-skin cancer among men and
the second leading cause of male cancer deaths
in the United States (Crawford 2003). There
were approximately 6.7 million cancer deaths
worldwide in 2002, and of these, prostate can-
cer was the ﬁfth most common overall and the
second most common among men (Parkin
et al. 2005). Migrant studies provide strong
evidence for the role of the environment in
prostate cancer. Throughout the last several
centuries, major migratory movements of
humans have taken place in many parts of the
world and continue even today. With increas-
ing length of stay, cancer mortality rates
among immigrants move toward those in the
adopted country. This has been clearly shown
for prostate cancer (McKay et al. 2003). There
are also intra- and interracial differences in
prostate cancer incidence and mortality rates
worldwide, and the environment and migra-
tion patterns seem to inﬂuence these dispari-
ties (Moradi et al. 1998; Stemmermann et al.
1991; Thomas and Karagas 1996). These
studies provide insight into the relative contri-
butions of heredity and environment in
prostate cancer.
Inorganic arsenic as a human carcinogen.
The NTP and the IARC have concluded that
arsenic is a human carcinogen (IARC 2004;
NTP 2004). Arsenic contamination of drink-
ing water is a common occurrence and a
worldwide public health issue. Some countries
have truly daunting issues with arsenic contam-
ination of drinking-water supplies, and
endemic chronic arsenicalism is observed in
many places in India, Bangladesh, Taiwan, and
China (IARC 2004). Although chronic arsenic
exposure produces a variety of adverse effects,
its carcinogenic potential in humans is perhaps
of greatest concern. Although the exact modes
of action remain to be deﬁned, it is reasonable
to assume that site-speciﬁc and multifactorial
mechanisms apply to inorganic arsenic. 
The carcinogenic potential of arsenic was
recognized over 100 years ago by Hutchinson
(1887), a British physician who observed skin
cancers occurring in patients treated with
medicinal arsenicals. Further evidence for
arsenic as a human carcinogen after industrial
exposure comes from studies of arsenic ore
smelters and pesticide workers (Brown and
Ross2002). In numerous countries it has been
shown that people who consume arsenic-cont-
aminated drinking water can develop various
cancers (IARC 2004; NRC 1999, 2001; NTP
2004). Thus, arsenic is a human carcinogen
after environmental, occupational, or medici-
nal exposures. Strong epidemiological associa-
tions exist between inorganic arsenic ingestion
and cancers of skin, urinary bladder, and lung.
Epidemiologic evidence has also linked arsenic
in the drinking water to prostate, kidney, and
liver cancers (IARC 2004; NRC 1999, 2001).
In fact, in its 2004 evaluation summary, the
most recent IARC monograph on arsenic
clearly states “Excess mortality from prostate
cancer was found in South-West Taiwan”
(IARC 2004). 
Data on concentrations of arsenic in
human target tissues, especially for internal
organs, are largely lacking. This factor
becomes problematic when attempting to
produce biokinetic models or when deﬁning
what are reasonable exposures for in vitro
studies. At least some human tissues, particu-
larly the skin, clearly will accumulate arsenic,
and skin levels in the range of 5,700 µg/kg
(~ 76 µM) have been reported from arsenic
intoxicated people in Bangladesh (IARC
2004). This is in contrast to circulating levels
of up to 60 µg/L (~ 0.8 µM) in blood and
274 µg/L (~ 3.6 µM) in urine during chronic
arsenic intoxication (NRC 1999). Thus, it is
unclear if circulating or excreted levels of
arsenic actually reflect target tissue or target
cell burden. Perhaps most important, there is
essentially no information on arsenic levels in
the human prostatic tissue. Clearly, further
work in this area is required.
Arsenic carcinogenesis in animals. Until
recently, inorganic arsenic in rodents was gen-
erally not carcinogenic except in model sys-
tems involving co-administration with known
carcinogenic agents (Germolec et al. 1998;
Rossman et al. 2004). However, a series of
studies from our laboratory [for review, see
Waalkes et al. (2007)] has recently demon-
strated that inorganic arsenite administered
during the second half of gestation to preg-
nant mice of several strains will induce or
impact the development of cancer in the off-
spring as adults in various tissues, including
tissues that are potential human targets such
as liver and lung. In studies using prenatal
arsenic exposure combined with exposure to
additional agents after birth, tumors of the
urinary bladder can also be induced. Together
these studies provide consistent evidence that
in utero arsenic is carcinogenic in mice and
targets several tissues that are concordant with
human target sites. 
However, prostate cancers do not develop
in these mouse studies (Waalkes et al. 2007).
In this regard, the genetically unaltered mouse
is not the rodent of choice for in vivo models
of human prostate cancer (Shirai et al. 2000).
The reasons for this include the observation
that mice are resistant to the induction of pro-
static tumors by chemical carcinogens as well
as differences in anatomy and pathophysiology
(Shirai et al. 2000). Transgenic mouse lines
are available in which prostate carcinomas
preferentially occur (Green et al. 1998; Shirai
et al. 2000), but arsenic has not been tested in
these models. Rats generally are considered a
better rodent model of prostate cancer because
prostate lesions can be chemically induced and
in the early stages are androgen dependent
(Shirai et al. 2000). However, arsenic bio-
kinetics in rats is very dissimilar to that in
humans or mice, and rats are considered a
poor model for human arsenic toxicology
(Aposhian and Aposhian 2006). Furthermore,
although pentavalent methylated arsenicals are
complete carcinogens and tumor promoters in
rats (Wanibuchi et al. 2004), they do not tar-
get the prostate. Thus, at present, whole
rodent prostate models of inorganic arsenic
carcinogenesis are not available.
Arsenic Exposure and Human
Prostate Cancer
The ﬁrst evidence that inorganic arsenic was
associated with prostate cancer in humans
came from Taiwan in the late 1980s (Chen
et al. 1988; Table 1). This was a follow-up
study that focused on dose–response relation-
ships between arsenic and cancer in a popula-
tion exposed to high levels of arsenic in the
drinking water from local artesian wells. The
population studied was from the area of
endemic “blackfoot” disease in southwest
Taiwan, a disease involving the peripheral vas-
cular dysfunction likely due, at least in part, to
arsenic exposure (Chen et al. 1985). Although
the original study had not looked at cancer of
the prostate (Chen et al. 1985), the subsequent
study found a remarkable association between
arsenic exposure and prostate cancer mortality
in this population (Chen et al. 1988). In this
Arsenic-induced prostate cancer
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Table 1. Epidemiologic studies of arsenic exposure and prostate cancer in humans.
Dose–response
Study Population location Source of arsenic Result relationship
Chen et al. 1988 Southwest Taiwana Drinking water Increased mortality Clear evidence
Wu et al. 1989 Southwest Taiwanb Drinking water  Increased mortality Clear evidence
Chen and Wang 1990 Taiwan Drinking water  Increased mortality Clear evidence
Tsai et al. 1999 Southwest Taiwan Drinking water  Increased mortality Not investigated
Lewis et al. 1999 Utah, USA Drinking water  Increased mortality Some evidencec
Hindwood et al. 1999 Victoria, Australia Local water/soil  Increased incidence No evidenced
aStudy focused on the area of endemic blackfoot disease. bThe Wu et al. (1989) study used the Chen et al. (1988) popula-
tion, with expansion into additional villages in the blackfoot-endemic area. cBased on the authors’ interpretation after
stratiﬁcation of data based on drinking-water levels. dThe rate of prostate cancer incidence was signiﬁcantly elevated at
the highest level of exposure when arsenic exposure was stratiﬁed based on arsenic in water and/or soil. When arsenic
exposure was stratified on water levels only (low, medium, high, and very high), prostate cancer incidence appeared
elevated in the high and very high categories [see Figure 3 in Hindwood et al. (1999)]. This did not, however, show a
signiﬁcant linear dose–response relationship.regard, the age-standardized mortality from
prostate cancer in the group exposed to the
highest levels of arsenic in the drinking water
(≥ 0.60 ppm) was nearly 6-fold greater than
that of the general population in Taiwan. In
addition, when drinking-water arsenic levels
were stratified (< 0.30 ppm, 0.30–0.59 ppm
and ≥ 0.60 ppm), a signiﬁcant dose–response
relationship occurred between arsenic level and
age-adjusted prostate cancer mortality. The
exposed population lived in a relatively small
area and had similar lifestyles, diets, living
conditions, and sociodemographic characteris-
tics compared with those of nearby unaffected
villages, prompting the authors to conclude
that the striking differences in cancer mortality
between these groups could be explained
“solely by the difference in arsenic concentra-
tions in drinking water” (Chen et al. 1988). 
Prostate cancer is not always fatal, particu-
larly in its early stages, and as the cause of
death was determined in this study by death
certiﬁcate (Chen et al. 1988), it is likely that
the rate of deaths would be much lower than
the incidence of prostate cancers in this popu-
lation. There were also large increases in mor-
tality from liver, lung, skin, bladder, and
kidney cancers in this population due to
arsenic exposure that generally exceeded the
rate of prostate cancer deaths (Chen et al.
1988). Therefore, other cancers may have
overshadowed relatively rare cancers of the
prostate. Furthermore, prostate cancer is usu-
ally a disease of older men, and because arsenic
is a very effective, multisite carcinogen, per-
haps some of the most sensitive subjects may
have died of other arsenic-induced cancers
before the development of advanced and
deadly prostate cancer. Indeed, prostate cancer
is considered to have a relatively low case-fatal-
ity rate (IARC 2004), making mortality as an
end point potentially insensitive of actual dis-
ease status, at least in the early stages.
A follow-up study to those of Chen et al.
(1985, 1988) concerning arsenic and cancer
mortality used some of the same population
at risk but added data from additional villages
in the area of endemic blackfoot disease and
specifically studied dose–response relation-
ships (Wu et al. 1989). In this study, the age-
adjusted mortality for prostate cancer in the
population exposed to the highest arsenic lev-
els in the drinking water (≥ 0.60 ppm) was
nearly 10-fold higher (9.18 deaths/100,000)
than that at the lowest level (< 0.30 ppm;
0.95 deaths/100,000) of exposure. A clear
dose–response relationship also occurred
between arsenic exposure and prostate cancer
mortality when drinking-water levels of
arsenic were stratiﬁed (< 0.30, 0.30–0.59, and
≥ 0.60 ppm) in this study. These interpreta-
tions must be tempered by the small number
of cancer deaths due to prostate cancer in this
study, but, nonetheless, the findings are
consistent with the prior work (Chen et al.
1988). Exposure levels were determined by
median village levels of arsenic in drinking-
water wells, and, as such, may be subject to
the “ecological fallacy” that the association
observed at the village level may not hold at
the individual level (Wu et al. 1989). Even
after considering this and other confounding
factors, the authors felt that arsenic content
should still be strongly suspected as the main
cause of excess cancer deaths in this popula-
tion (Wu et al. 1989).
In subsequent work from Taiwan, the
study population was expanded from the area
of endemic blackfoot disease used in the ﬁrst
two studies (Chen et al. 1988; Wu et al.
1989) to a much more comprehensive study
of all 314 precincts and townships in Taiwan
as a whole. In all, 83,656 wells were tested for
arsenic (Chen and Wang 1990). Based on
multiple regression analysis with adjustments
for urbanization and age, mortality rates from
cancer of the prostate again increased in cor-
relation with increasing average drinking-
water level of arsenic.
In an independent study of the area of
endemic blackfoot disease in southwest
Taiwan, Tsai et al. (1999) computed age-
adjusted standardized mortality ratios (SMRs)
using death certiﬁcates with national reference
rates. The SMR for prostate cancer in the
arsenic-exposed population was 1.96, with a
95% confidence interval (CI) of 1.4–2.6,
indicating a signiﬁcant increase in the number
of observed cases compared with the number
of expected based on the national reference
rates. The number of observed cases in this
arsenic-exposed population was 48, and
dose–response effects were not investigated. 
The role of drinking-water arsenic in
prostate cancer mortality has also been stud-
ied in a U.S. population (Lewis et al. 1999).
Mortality was assessed in a retrospective
cohort of Millard County, Utah, residents
along with drinking-water arsenic exposure
levels that accounted for residence time in the
study area. The cohort consisted of 2,073
members with at least 20 years of exposure
history and was assembled through member-
ship records of the Church of Jesus Christ of
Latter-day Saints. Arsenic exposure was strati-
fied into low (< 1,000 ppb-years), medium
(1,000–4,999 ppb-years) and high (≥ 5,000
ppb-years) levels (Lewis et al. 1999). Without
considering specific arsenic exposure levels,
the overall SMR for prostate cancer mortality
was signiﬁcantly elevated in the cohort (1.45;
95% CI, 1.07–1.91, based on 50 deaths)
compared with that of Utah white males. The
authors indicate that SMR analysis hinted at a
dose–response relationship when based on
low (SMR = 1.07), medium [1.70 (signifi-
cantly elevated)] and high (1.65) arsenic
exposure (Lewis et al. 1999).
In a study from Australia, geographic areas
with soil arsenic > 100 mg/kg and/or drinking-
water concentrations > 0.01 mg/L were
selected and related to cancer incidence
(Hinwood et al. 1999). Standardized incidence
ratios (SIRs) were generated for 22 areas of ele-
vated arsenic exposure in Victoria and com-
pared with all Victorian cancer rates as a
baseline. For all areas with any elevated arsenic
(soil or water or both), the SIR was signifi-
cantly increased for prostate cancer (1.14; 95%
CI, 1.05–1.23). Exposure was also stratiﬁed as
only high soil or only high water arsenic (low)
or both high soil and high water arsenic (high).
When arsenic exposure was stratiﬁed by expo-
sure type (i.e., high water only, high soil only,
high water/high soil), the SIR for prostate can-
cer remained signiﬁcantly elevated (1.20; 95%
CI, 1.06–1.36), in the high water/high soil cat-
egory. Dose–response analysis was performed
on data stratified based on water content of
arsenic as low (< 0.01 mg/L), medium
(0.01–0.1 mg/L), high (0.1–0.2 mg/L), and
very high (> 0.2 mg/L) levels. No linear dose
response was detected for prostate cancer inci-
dence using this water stratiﬁcation, but based
on graphical presentation, the SIRs for the
high and very high categories appeared elevated
(95% CIs did not include 1.0). The study
included 619 cases of prostate cancer. The
authors make the point that of those targets
expected a priori from other studies, only
prostate cancer was signiﬁcantly elevated. 
In a population of male copper foundry
workers industrially exposed to arsenic as well as
other metals, a correlative survey of plasma neo-
plastic biomarkers was conducted (Szymanska-
Chabowska et al. 2004). A strong positive
correlation occurred between urinary arsenic
concentration and serum prostate-speciﬁc anti-
gen (PSA). PSA is a well-established biomarker
for prostate cancer that is considered a main-
stay of early prostate cancer detection. The
exposure to other metals complicates interpre-
tation of this study, but the correlation
between arsenic in the urine and circulating
PSA was robust. In this regard, tumors arising
from human prostate epithelial cells trans-
formed by inorganic arsenic in vitro also show
a remarkable overexpression of PSA (Achanzar
et al. 2002).
The results of various positive studies of
prostate cancer and arsenic exposure were
considered as a whole by the IARC (2004).
The specific conclusion was that “data from
southwest Taiwan indicate a consistent pat-
tern of increased mortality from prostate can-
cer in areas with high contamination by
arsenic, and there is evidence of a dose-related
effect” (IARC 2004). Although the prostate
was not specifically mentioned as a human
target site in the ﬁnal evaluation of the mono-
graph, the implications of the text are clear
and, at least in part, are supported by the data
Benbrahim-Tallaa and Waalkes
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make it less likely that the Taiwanese are
uniquely sensitive. Whatever the conclusion,
the available evidence indicates an obvious
need for additional studies of arsenic as a
human prostatic carcinogen. 
As a potential complicating factor in
dose–response analysis, evidence indicates that
arsenic can adversely affect testicular function
in animals, even at levels near the range for
some human exposure situations. This includes
loss of testicular weight, diminished sperm
count, and decreased 17β-hydroxysteroid
dehydrogenase (17β-HSD) activity in mice
chronically given 4 ppm arsenic in the drinking-
water (Pant et al. 2004). In this regard,
17β-HSD is an enzyme important in produc-
tion of testosterone from its immediate precur-
sors, such as androstenedione. Similarly, in rats
chronic oral arsenic exposure decreases testicu-
lar weight, sperm count, testicular 17β-HSD
activity, and plasma and testicular testosterone
concentrations (Jana et al. 2006). Prostate can-
cer, particularly in its early stages, is dependent
typically on circulating androgens and will
regress with orchiectomy and/or antiandrogen
therapy, two strategies commonly used in
prostate cancer treatment (Kyprianou and
Isaacs 1988). Thus, if higher doses of arsenic
similarly suppressed testosterone production in
humans, this could complicate the dose–
response analysis by potentially diminishing
carcinogenic response at higher doses. There is
no direct evidence of this in humans, however.
In Vitro Model of Arsenic-
Induced Prostatic
Carcinogenesis
In vitro models can be invaluable for studies on
carcinogenic mechanisms and can be applied
to the various stages of oncogenesis including
initiation and progression. In fact, those
employing human cells can provide carefully
controlled exposure circumstances that are
impossible in environmentally exposed human
populations. Cell model systems have been
used to identify molecular markers of transfor-
mation during prostate cancer development. In
this regard, the majority of commonly used
human prostate cell lines are derived from
biopsies of metastatic prostate cancer (Webber
et al. 1996a, 1997) and, as such, would be
more appropriate for deﬁning molecular events
occurring during tumor progression to
advanced prostate cancer. Prostate cancer has
the added aspect of acquired androgen inde-
pendence, generally occurring as a progression
to a deadly form of the disease. Hence, tumor-
derived cell lines have been used to extensively
study androgen independence (Gustavsson
et al. 2005). For the study of carcinogenic
initiation, one would want a nontransformed
(“normal”) line that is nontumorigenic upon
inoculation into mice. Human arsenic exposure
is typically to an acutely tolerable dose over
long periods of time. To use doses (concentra-
tions) similar to human exposure, cells should
be exposed to relatively low levels of arsenic for
protracted periods. Hence, an immortalized
cell line is essential. 
The human prostate epithelial cell line
RWPE-1 was originally derived from normal
human prostate epithelium (Bello et al. 1997;
Webber et al. 1997). RWPE-1 cells are
immortalized and nontumorigenic upon inoc-
ulation into immunocompromised mice, an
important observation, as the ability to form
tumors is a key element in the definition of
cellular malignant transformation. By contin-
uous exposure of this line to low levels of inor-
ganic arsenic over a period of several months,
a malignant transformant was developed
(Achanzar et al. 2002). Essentially, RWPE-1
cells were cultured in the presence of 5 µM
arsenic continuously for up to 30 weeks, while
parallel control cultures served as passage-
matched controls. Cell samples were frozen
periodically to allow for assessment of time-
course changes after conﬁrmation of transfor-
mation. This chronic arsenic-exposed prostate
epithelial (CAsE-PE) cell line, showed a
2.2-fold increase in matrix metalloproteinase-9
(MMP-9) secretion compared with control
(Achanzar et al. 2002). Increased MMP-9 is
associated with Ras-induced or cadmium-
induced malignant transformation of RWPE-1
cells (Achanzar et al. 2001; Webber et al.
1996b), occurs in human prostate tumors and
in primary cultures of prostatic cancer cells,
and is associated with aggressive prostatic
malignancies (Hamdy et al. 1994). When
CAsE-PE cells were inoculated into the renal
capsule of nude mice, all of the mice inocu-
lated developed tumors within 10 weeks while
control cells remained nontumorigenic
(Achanzar et al. 2002). The aggressive carci-
noma that developed from CAsE-PE inocula-
tion showed several characteristics in common
with human prostatic cancers, including
overproduction of human PSA (Achanzar
et al. 2002), clearly indicating their origin.
The rapidly formed tumors resulting from
CAsE-PE cell inoculation often invaded local
tissue (Achanzar et al. 2002). Because animal
models for arsenic carcinogenesis are currently
absent for the prostate, this in vitro system has
been used to help deﬁne the molecular events
in arsenic-induced prostatic carcinogenesis.
Indeed, these cells and their heterotransplanta-
tion tumors show a remarkable series of char-
acteristics in common with human prostate
carcinoma (Table 2). The ﬁnding that human
prostate epithelial cells are directly susceptible
to arsenic-induced malignant transformation
strongly fortifies the evidence for a potential
role of arsenic in human prostate cancer.
Molecular Events in Arsenic-
Induced Malignant
Transformation
Several studies were conducted to examine the
molecular events in arsenic-induced malignant
transformation in human prostate cells, includ-
ing studies on DNA methylation (Benbrahim-
Tallaa et al. 2005a). Inorganic arsenic
biomethylation uses SAM as the methyl donor,
and SAM depletion can induce DNA hypo-
methylation (Loenen 2006). Indeed, in
CAsE-PE cells arsenic-induced malignant
transformation also induces genomic DNA
hypomethylation (Benbrahim-Tallaa et al.
2005a). A decrease of DNA methyltransferase
activity is an early event occurring before
malignant transformation and may account for
the subsequent genomic DNA hypomethyla-
tion (Benbrahim-Tallaa et al. 2005a). Arsenic-
induced DNA hypomethylation occurs in
malignantly transformed rodent liver cells
(Zhao et al. 1997) and in the liver of mice after
chronic exposure to inorganic arsenic (Chen
et al. 2004). Furthermore, hepatocellular carci-
noma induced by transplacental exposure to
inorganic arsenic in mice is associated with
aberrant gene expression changes likely due, at
Arsenic-induced prostate cancer
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Table 2. Characteristics in common between human prostate carcinoma cells and arsenic-transformed
human prostate epithelial cells.
Human Arsenic-transformed
Characteristic prostate carcinoma cells References
Hyperproliferative + + Achanzar et al. 2001
Benbrahim-Tallaa et al. 2005b
MMP-9 overexpression + + Achanzar et al. 2001
Benbrahim-Tallaa et al. 2005a
Tumor formation + + Achanzar et al. 2001
PSA overexpression + + Achanzar et al. 2001
Benbrahim-Tallaa et al. 2005b
Benbrahim-Tallaa et al. 2007
Unmutated ras overexpression + + Benbrahim-Tallaa et al. 2005a
Benbrahim-Tallaa et al. 2007
Acquired androgen independence + + Benbrahim-Tallaa et al. 2005b
through AR by-pass Benbrahim-Tallaa et al. 2007
HER-2/neu overexpression + + Benbrahim-Tallaa et al. 2007
Invasive + +a Achanzar et al. 2001
aIn tumors formed by heterotransplant of CAsE-PE cells.least in part, to errors in DNA methylation
including hypomethylation of steroid signaling
transcription factors (Waalkes et al. 2004). The
ﬁnding of arsenic-induced DNA hypomethyla-
tion in human prostate cells indicates this may
be a plausible contributing factor for tumor
development in arsenic-exposed human popu-
lations (Benbrahim-Tallaa et al. 2005a).
Carcinogenesis can result from aberrations of
genomic DNA methylation that include
hypomethylation of the promoter of cancer-
related genes. Global hypomethylation of
genomic DNA is often observed in tumors and
contributes to overexpression of proto-
oncogenes, growth factors, and genes that are
involved in cancer cell proliferation, invasion,
and metastasis (Stirzaker et al. 2004). DNA
hypomethylation is viewed as a nongenotoxic
mechanism facilitating aberrant gene expres-
sion (Counts and Goodman 1995; Vorce and
Goodman 1989). Aberrant gene expression is a
common occurrence in arsenic-exposed cells.
Studies show that both CAsE-PE and
parental cells have a very poor capacity to
methylate arsenic, making competition for
SAM an unlikely basis for arsenic-induced
DNA hypomethylation (Benbrahim-Tallaa
et al. 2005a). There is, however, emerging evi-
dence that during cellular adaptation to
chronic arsenic exposure, SAM recycling may
be reduced in order to overproduce glutathione
for arsenic efﬂux through transsulfuration of
homocysteine (Coppin et al. 2007).
A marked overexpression of unmutated
K-ras was also observed in CAsE-PE cells
(Benbrahim-Tallaa et al. 2005a). Although
hypomethylation of the ras gene can lead to
activation, the K-ras promoter region, includ-
ing the major transcriptional initiation site, was
essentially unmethylated in both control and
CAsE-PE cells (Benbrahim-Tallaa et al.
2005a). Thus, although genomic DNA
hypomethylation was observed in arsenic-
transformed cells, this does not appear to be
the direct cause of overexpression of K-ras
(Benbrahim-Tallaa et al. 2005a). Whatever the
basis, K-ras overexpression appears to have
been a key molecular change associated with
arsenic-induced transformation of CAsE-PE
cells. K-ras overexpression was observed as early
as 12 weeks after arsenic exposure and reached
its highest level after approximately 30 weeks
of continuous arsenic exposure, the time point
for malignant transformation. This is consis-
tent with previous data suggesting that K-ras
amplification could be an early event in the
pathogenesis of prostatic carcinogenesis (Lau
et al. 2004) and may be a critical factor that
drives prostate cancer development (Weber
and Gioeli 2004). Thus, the in vitro prostate
model of arsenic carcinogenesis (Benbrahim-
Tallaa et al. 2005a) duplicates this key aspect
of the corollary disease in humans (Table 2). 
The normal development, growth, and sur-
vival of the prostate epithelium are regulated
both by systemic and local androgen and by
local production of growth factors by the pro-
static stroma (Feldman and Feldman 2001).
However, regulatory interactions between
androgens and growth factors often become
distorted in prostate cancer (Feldman and
Feldman 2001). Ras is a critical signaling mole-
cule that controls several signaling pathways in
prostate cancer (Gioeli 2005; Weber and Gioeli
2004). Yet, ras mutations are infrequent in
prostate cancer (Carter et al. 1990). This is con-
sistent with the hypothesis that wild-type ras is
chronically activated by autocrine and paracrine
factor stimulation in prostate cancer (Gioeli
2005; Weber and Gioeli 2004). Virtually all the
growth factor receptors upregulated in prostate
cancer activate ras for their signal transduction
activity (Gioeli 2005). In essence, ras signaling
represents a convergence point for numerous
diverse extracellular signals in prostate cancer
(Gioeli 2005). One of the best-characterized
effector pathways triggered by Ras activation is
the MAPK (serine–threonine protein kinases)
pathway. The activation of K-ras by arsenic in
CAsE-PE cells is by some mechanism other
than promoter region hypomethylation, per-
haps involving genes upstream of ras
(Benbrahim-Tallaa et al. 2005a). In this regard,
a series of proteins participating in protein–pro-
tein interactions are responsible for the control
of ras activation and include Raf (c-Raf-1,
A-Raf, and B-Raf), MEK (MAPK/ERK
kinases 1 and 2), and ERK1/2 (McCubrey et al.
2006). The ERK1/2 signaling pathway plays an
important role in cellular growth and differenti-
ation (McCubrey et al. 2006). Thus, molecular
events upstream of ras have been compared in
CAsE-PE and control cells. Clearly, proteins
upstream of K-ras, including A-Raf and B-Raf
showed greatly increased expression in
CAsE-PE cells compared with control
(Benbrahim-Tallaa et al. 2007). There was also
an increased expression of phosphorylated
MEK1/2 and ELK in CAsE-PE cells compared
with control (Benbrahim-Tallaa et al. 2007).
Thus, there is a correlation between elevated
levels of active phosphor-MAPK and arsenic-
induced prostate cell transformation. 
Prostate cancer is a leading cause of male
cancer death because in its advanced stages it
acquires androgen independence and becomes
Benbrahim-Tallaa and Waalkes
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Figure 1. Mechanisms of arsenic-induced acquired androgen independence. Abbreviations: AR, androgen
receptor; ARE, androgen responsive element; As, arsenic; GF, growth factors; MAPK, mitogen-activated
protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPK kinase kinase; PSA, prostate-speciﬁc antigen. It is
known that exposureto arsenic initiates GF receptor signaling and Ras-dependent activationof MEK1/2 and
ERK1/2. (A) As prostate cancer progresses to androgen independence, the growth factors production
increases. Growth factor signal transduction pathways have been shown to stimulate AR activation. All
these growth factors use the Ras/MAPK pathway for a portion of their signal transduction. Binding of GF
results in dimerization, autophosphorylation of the receptor, and tyrosine phosphorylation of other proteins.
The GF receptor activates ras which in turn activates Raf, which phosphorylates and activates MEK, which
in turn, phophorylates and activates ERK. Activated MAPK can regulate targets in the cytosol and also
translocate to the nucleus causing phosphorylation of transcription factors such as c-Fos to create AP-1
and ELK-1, which contribute to proliferation. (B) HER-2/neu promotes phosphorylation of AR at multiple sites
even in the presence of very low androgen levels. HER-2/neu indirectly activates MAPK. MAPK might phos-
phorylate the AR, creating an androgen-independent receptor.resistant to androgen ablation therapy. Surgery
can cure locally conﬁned prostate cancer, but
there are currently no effective treatments for
androgen-independent, metastatic prostate
cancer. When prostate cancer progresses in this
manner, it is variously called “androgen inde-
pendent” or “hormone refractory,” because it is
resistant to hormone ablation therapy.
However, evidence indicates advanced prostate
cancers often are not fully independent of
androgen, but rather have become hypersensi-
tive even to very low levels of androgen (Weber
and Gioeli 2004). A majority of prostate
tumors obtained from patients failing andro-
gen ablation therapy overexpress the androgen
receptor (AR), sensitizing the cells to low levels
of androgen (Linja et al. 2001). This over-
expression is often associated with gene ampli-
ﬁcation (Linja et al. 2001). Frequently, the AR
is mutated in advanced prostate cancers, which
results in a receptor that can be activated by
nonandrogens (Culig et al. 2001). Because the
Ras/MAPK signaling pathway can also reduce
the androgen requirement of prostate cells
(Bakin et al. 2003), one would predict that
stimulation of this signaling pathway might
allow androgen-regulated gene expression even
at very low levels of androgen. Evidence sug-
gests that the Raf/MEK/ERK pathway plays a
critical role in the modulation of AR activity in
response to ras (Gioeli 2005). In addition,
MAP kinase activity correlates with progression
to an increasingly advanced and hormone-
independent stage (Gioeli et al. 1999). 
CAsE-PE cells, in which chronic arsenic
exposure induced malignant transformation,
hyperproliferation, and overexpression of K-ras
(Benbrahim-Tallaa et al. 2005a), have also been
used to help define the role of arsenic in
prostate cancer progression. The evidence
shows CAsE-PE cells clearly acquired androgen
independence during transformation that is not
associated with AR overexpression (Benbrahim-
Tallaa et al. 2005b). The AR in CAsE-PE cells
actually is less responsive to androgen, indicat-
ing an AR mutation that causes hypersensitivity
to androgens is unlikely (Benbrahim-Tallaa
et al. 2005b, 2007). In addition, alterations in
androgen metabolism, estrogen production,
and estrogen receptor levels and sensitivity 
also had limited roles in this conversion
(Benbrahim-Tallaa et al. 2005b, 2007).
However, the overexpression of HER-2/neu is a
prominent feature (Benbrahim-Tallaa et al.
2007) and one in which CAsE-PE cells have in
common with androgen-independent human
prostate carcinoma (Table 2). Thus, it appears
arsenic-induced malignant transformation pre-
cipitates upregulation of ras, which in turn,
allows by-pass of AR to induce androgen inde-
pendence in human prostate epithelial cells
(Figure 1). The fact that a common environ-
mental contaminant such as arsenic can induce
prostate tumor cells to progress to a much more
lethal state could be very important in human
populations exposed to this metalloid. 
Overall the CAsE-PE cells and their het-
erotransplantation tumors show a remarkable
series of traits in common with advanced
human prostate carcinoma (Table 2).
Conclusions
It has been known for over a century that inor-
ganic arsenic is a human carcinogen. Arsenic
exposure affects millions of people worldwide.
Various studies in human populations exposed
to arsenic via the environment provide evi-
dence of a causal link to prostate cancer. In
many cases this association is dose related,
adding further evidence for an etiological role
for the metalloid in this important human can-
cer. Rodent models of inorganic arsenic car-
cinogenesis generally have been slow to
develop and have not specifically shown the
prostate as a target of inorganic arsenic carcino-
genesis. The rat, which is a species of choice for
animal models of human prostate cancer, is
unfortunately a poor choice for modeling
human arsenic toxicity. Various studies using
human prostate epithelial cells in culture have
shown that low-level inorganic arsenic expo-
sure can induce malignant transformation
specifically in these cells. The finding that
human prostate epithelial cells are directly sen-
sitive to malignant transformation induced by
inorganic arsenic strongly supports a potential
role for arsenic in human prostate cancer.
Heterotransplantation of these cells into nude
mice produced aggressive carcinomas that
overexpress PSA in a fashion similar to human
prostate carcinoma. In addition, inorganic
arsenic stimulates acquired androgen indepen-
dence during this malignant transformation, a
condition associated with advanced human
prostate cancer and poor prognosis. The cancer
risk at low doses of arsenic is a subject of con-
siderable debate and may not be solved solely
by epidemiologic means, particularly for target
sites such as the prostate, for which there are
currently no whole-animal models. Therefore,
it is essential to learn more about arsenic’s
mode of action at the target cell level. Arsenic
seems to have the potential for many mecha-
nisms of action in the development of cancer,
including prostate cancer. Finally, additional
research is clearly needed at all levels on the
role of arsenic in prostate cancer development
and progression. 
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